EMPEROR-Reduced and EMPEROR-Preserved
The aim of the EMPEROR-Reduced, as well as the EMPEROR-Preserved studies is to investigate the safety and efficacy of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure and either reduced ejection fraction or preserved ejection fraction.
This study evaluates the following outcome measures:
- Time to first event of adjudicated CV (Cardiovascular) death or adjudicated HHF (Hospitalization for Heart Failure) in patients with Heart Failure with reduced or preserved Ejection Fraction (HFrEF).
- Occurrence of adjudicated HHF.
- eGRF (Estimated Glomerular filtration Rate), CKD-EPI (Chronic Kidney Disease-Epidemiology collaboration Equation), and cr slope of change from baseline.
- Time to first occurrence of chronic dialysis or renal transplant or sustained reduction of eGFR.
- Time to first adjudicated HHF.
- Time to adjudicated CV death.
- Time to all-cause mortality.
- Time to onset of DM (Diabetes Mellitus).
- Change from baseline in clinical summary score (Chronic Heart Failure symptom and physical limitations domains) of the Kansas City Cardiomyopathy Questionnaire at week 52.
- Occurrence of all-cause hospitalization (first and recurrent) – time frame up to 38 months.
“While there are medications for the treatment of heart failure, 50% of patients with congestive heart failure will still die within 5 years. Thus, there is an unmet need for additional medications to treat heart failure. This medication, while invented for the treatment of diabetes, may have direct heart benefit, a premise that is being tested in these two trials.” Cara East, MD, principal investigator.
Main/critical inclusion and exclusion criteria:
A complete list of inclusion and exclusion criteria for the reduced ejection fraction study can be found at:
A complete list of inclusion and exclusion criteria for the preserved ejection fraction study can be found at:
Merielle Boatman, MBA, BAAS, Merielle.Boatman@BSWHealth.org
Back to Clinical Trials